Last updated 12 days ago
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
888 patients around the world
Available in Mexico, United States
Eli Lilly and Company
6Research sites
888Patients around the world
This study is for people with
Diabetes
Diabetes mellitus type 2
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have a clinical diagnosis of T2D based on the World Health Organization classification or other locally applicable diagnostic standards.Have HbA1c ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.Have been on stable diabetes treatment with metformin ≥1500 milligram per day (mg/day) during the 90 days prior to screening and maintained through randomization.Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.Have a body mass index (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.
- Have Type 1 Diabetes (T1D)Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edemaHave an estimated glomerular filtration rate (eGFR) <45 milliliter per minute (mL/min)/1.73 square meter (m2)Have acute or chronic hepatitisHave had chronic or acute pancreatitis any time.Have been treated with any antihyperglycemic medication (other than metformin) within the 90 days prior to screening.
Sites
Cryptex Investigación Clínica
IDON S.C Instituto de Diabetes, Obesidad y Nutricion
Cardiolink Clin Trials, S.C
Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada, S.C. - SINACOR
Consultorio de Medicina especializada del Sector Privado
Lahoja Asociación para la Investigación y Farmacovigilancia
StudyACHIEVE-2
SponsorEli Lilly and Company
Conditions
Diabetes mellitus type 2
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06192108
